Johnson & Johnson's recent submission of a supplemental New Drug Application for CAPLYTA® could further strengthen its footing in the mental health space. Estimated potential is for CAPLYTA to achieve over US$5 billion in peak sales, so this development aligns well with the company's strategy to bolster revenue through innovative medicines, even as it faces challenges such as the loss of exclusivity for STELARA.
https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-submits-172658969.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.